Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of erlotinib in treating patients who have
unresectable liver cancer and liver dysfunction. Biological therapies such as erlotinib may
interfere with the growth of tumor cells and slow the growth of the tumor